Best Biopharma Outsourcing Companies in San Diego, United States
The 81 best Biopharma Outsourcing companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Resilience.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in San Diego
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Resilience Provider of supply chain services for biopharma sector 72Funding top 15%Product top 26%Innovation top 30%Growth top 35% All 9 signals ▾Fundingtop 15% Producttop 26% Innovationtop 30% Growthtop 35% Markettop 43% Techtop 43% Talentbottom 49% Globalbottom 38% Moatbottom 38% Funding: Raised $2.0B across 10 rounds · 10 rounds over 20 yrs (0.5/yr) Product: 3 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 72/100 | $2.0B | 7 mo ago | 1,767 | 1995 | Rahul Singhvi ex-Co-Founder | HubSpot CMS HubApple iCloud MailMicrosoft 365+23 | — | 1 expansion |
| 2 | Societal CDMO Provider of clinical trial, formulation development, packaging, and quality assurance services | $141M | 103 mo ago | 275 | 1982 | — | — | — | — |
| 3 | Certis Oncology Solutions Provider of oncology-based in-vivo drugs development services | $42M | 29 mo ago | 41 41 → 39 (-5%) | 2016 | James Berglund Founder & Director | — | 12 patents Patents concentrated in computing, sensing & instrumentation | 1 partnership |
| 4 | Optimer Pharmaceuticals Limited information available | $40M | 201 mo ago | 281 | 1998 | — | — | 152 patents Fidaxomicin-based antibiotics for treating Clostridioides difficile and recurrent bacterial infections | — |
| 5 | Ocelot Bio CDMO focused on manufacturing of peptides | $36M | 62 mo ago | 20 | 2020 | — | — | — | — |
| 6 | BioIntervene Limited information available | $36M | 60 mo ago | — | 2014 | Daniela Salvemini Co-Founder | — | 13 patents Design and synthesis of therapeutic adenosine analogs and A3 receptor agonists. | — |
| 7 | Inception Therapeutics Provider of biopharma consulting services | $35M | 126 mo ago | 25 | 2011 | — | Apache HTTP ServerMicrosoft 365jQuery+2 | — | — |
| 8 | Anabios Human tissue and cell provider accelerating drug discovery and development | $25M | 48 mo ago | 51 51 → 38 (-25%) | 2009 | — | — | 15 patents Cardiac safety pharmacology predictive models and ex‑vivo sensory neuron subtype profiling | — |
| 9 | Althea Technologies Contract-based manufacturer and distributor of clinical drugs and vaccines | $23M | 233 mo ago | 220 | 1998 | Francois Ferre Co-Founder & CEO | — | 64 patents Protein crystal engineering for biopharma enzymes and therapeutic protein formulations | — |
| 10 | Ainos Company focused on the development of novel point-of-care testing and low-dose interferon therapeutics | $13M | 25 mo ago | 43 | 1986 | Chun Tsai CEO | DudaApple iCloud MailMicrosoft 365+12 | 24 patents Electronic nose and gas‑sensor systems for rapid chemical/medical diagnostics | — |
| 11 | NanoImaging Services Provider of cryo-electron microscopy, protein production, and nanoparticle characterization services | $9M | 21 mo ago | 44 44 → 40 (-9%) | 2007 | Clint Potter Co-Founder | WebflowApple iCloud MailMicrosoft 365+19 | 2 patents Electron microscopy and image analysis for particulate characterization | 1 launch |
| 12 | IriSys CDMO specializing in the development of a wide range of dosage forms | $6M | 136 mo ago | 59 | 1996 | — | — | 13 patents Liposomal formulations for targeted delivery of anticancer and antitumor agents. | — |
| 13 | eStudySite Integrated research sites accelerating therapy delivery and providing exceptional patient care | $6M | 234 mo ago | 5 | 1999 | — | — | — | — |
| 14 | Excellos CDMO focused on providing manufacturing services for cell & gene therapy products | $5M | 25 mo ago | 32 | 2010 | David Wellis CEO | — | — | — |
| 15 | Cellebration Life Sciences Provider of research, development, and manufacturing services for biologic drugs | $3M | 34 mo ago | 8 | 2019 | Tim Kopatich Co-Founder & CEO | — | — | — |
| 16 | Therapeutics Dermatology CRO providing integrated solutions for drug development and regulatory approval | $3M | 184 mo ago | 91 | 1997 | — | — | 1,872 patents Targeted protein degradation (PROTACs) and exosome-based therapeutics for oncology and neurodegeneration | — |
| 17 | PhenoVista High-content imaging and analysis services to accelerate drug discovery | $3M | 41 mo ago | 36 | 2014 | — | HubSpot CMS HubLazySizescore-js+13 | — | — |
| 18 | Afraxis Provider of CNS pharmaceutical screening technologies to evaluate pre-clinical therapeutics | $2M | 105 mo ago | 14 | 2007 | — | — | 138 patents PAK kinase inhibitor therapeutics and AI-driven distributed anatomical imaging platforms | — |
| 19 | Percept Provider of drug repurposing engine for combination therapeutics clinical development | $570K | 14 mo ago | — | 2023 | Thomas Zheng Co-Founder | — | 30 patents Adaptive personalized optical eyewear integrating eye‑tracking, display and vision‑enhancement technologies. | — |
| 20 | Nano PharmaSolutions CDMO focused on manufacturing of APIs | $351K | 58 mo ago | 3 | 2019 | — | — | — | 2 partnerships |
| 21 | Epochbio Developer and seller of proprietary products with commercial applications in the genomics and molecular… | $339K | 214 mo ago | 35 | 2000 | — | — | — | — |
| 22 | ExonBio Recombinant antibody development for diagnostics and research applications | $325K | 192 mo ago | 12 | 1996 | — | Cart FunctionalityWooCommerceWordPress+25 | — | — |
| 23 | VisiCELL Medical Developer of MRI-based in vivo imaging analytics for cell therapy | $276K | 51 mo ago | 13 | 2012 | Mya Thu Co-Founder & CEO | — | — | — |
| 24 | ChemDiv Preclinical CRO offering integrated services from target to clinic stage of drug development | $275K | 237 mo ago | 14 | 1990 | — | Cart Functionality1C-BitrixPHP+14 | 2 patents Selective estrogen receptor and GPR30 modulators for therapeutic applications | 1 launch · 1 partnership |
| 25 | Tioga Research Topical and transdermal drug development experts accelerating formulation with innovative technologies | $256K | 105 mo ago | 11 11 → 7 (-36%) | 2011 | John M Newsam Co-Founder & CEO | WordPressMySQLPHP+17 | — | — |
| 26 | BioBlocks Drug discovery CRO providing integrated services from target to clinical trials | $116K | 89 mo ago | 3 | 2000 | Peter Pallai Founder & CEO | — | 7 patents Small-molecule kinase inhibitor libraries for drug discovery and screening | — |
Top 12 Biopharma Outsourcing companies in San Diego
#1
Series D · San Diego, California · founded 1995 · 1767 employees$2Braised▾
Provider of supply chain services for biopharma sector
- Oct 2025Venture Debt$825M
- Oct 2024Grant (prize money)$17.5M
- Mar 2023Conventional Debt$410M
- Jan 2023Series D—
#2
Series A · San Diego, California · founded 2007 · 44 employees$9Mraised▾
Provider of cryo-electron microscopy, protein production, and nanoparticle characterization services. They offer structural biology solutions, including sample preparation and computational infrastructure. The company’s services support structure-based drug design. They also offer method validation services.
- Sep 2024Series A$12.2M
- Jun 2023Series A—
- Jun 2021Grant (prize money)$1.1M
- Jun 2014Grant (prize money)$223.2K
#3
Funding Raised · San Diego, California · founded 2023$569.9Kraised▾
Provider of drug repurposing engine for combination therapeutics clinical development. It offers an engine that integrates qualitative knowledge with quantitative data to identify synergistic drug combinations and assess molecule fit across indications. The engine aims to provide a path towards commercialization of drug combinations.
- Mar 2025Grant (prize money)$294.9K
- Jul 2024Grant (prize money)$274.9K
#4
Series C · San Diego, California · founded 2016 · 41 employees$42Mraised▾
Certis Oncology Solutions provides oncology-based in-vivo services for pharmaceuticals and biotech companies. They have developed Certis Orthotopic PDX techniques (patient-derived orthotopic xenografts) which replicate human tumor growth, metastasis, and response to therapy.
- Jan 2024Series C$10M
- Nov 2023Series A$3.7M
#5
Public · San Diego, California · founded 1986 · 43 employees$12.7Mraised▾
It is a diversified medtech company that is focused on transforming itself into a leader in the field. They are developing innovative business arms in pharmaceuticals, point-of-care testing, and low-dose interferon therapeutics. Ainos is also involved in the development of new drug candidates and health supplements.
- May 2024Post IPO$9M
- Jan 2024Post IPO—
- Sep 2023Post IPO—
- Aug 2018Post IPO$721K
#6
Series A · San Diego, California · founded 2010 · 32 employees$5Mraised▾
CDMO focused on providing manufacturing services for cell & gene therapy products
- May 2024Series A—
- Aug 2023Series A$5M
#7
Series B · San Diego, California · founded 2009 · 51 employees$24.8Mraised▾
Human tissue and cell provider accelerating drug discovery and development. They offer high-quality human tissue and cells to advance scientific research and drug discovery. They utilize proprietary methods to maximize the preservation of physiological function in human tissues. They provide human data to ensure the selection of the most effective and safest drugs. Their services include target identification, lead identification, and lead optimization using authentic human targets. They support mechanistic studies to de-convolute clinical stage toxicity signals. They focus on areas of high, unmet medical need, including cardiac disease and safety, pain, and neurodegeneration. They offer functional assays, including CardioPRIME, heart tissue assays, neurotoxicity assays, and pain-related assays. They provide human hepatocytes, precision-cut lung slices, DRG tissue, kidney tissue, heart tissue, brain tissue, and spinal cord tissue. They enable human-focused drug discovery and accelerate development.
- Jun 2022Series B$6.5M
- Sep 2021Grant (prize money)$1.7M
- Sep 2021Grant (prize money)$1.4M
- Sep 2020Grant (prize money)$320.1K
#8
Acquired · San Diego, California · founded 1982 · 275 employees$141Mraised▾
Provider of clinical trial, formulation development, packaging, and quality assurance services
- Nov 2017Conventional Debt$125M
- Jul 2015Post IPO$16M
#9
Series A · San Diego, California · founded 2014$35.6Mraised▾
Developer of first-in-class and selective A3 adenosine receptor analgesics intended to treat neuropathic pain. The company focuses on discovering and developing effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders, enabling pharmaceutical companies to treat neuro pains and other related problems.
- Jun 2021Series A$5.6M
- Jan 2020Series A$30M
#10
Deadpooled · San Diego, California · founded 2020 · 20 employees$36Mraised▾
CDMO focused on manufacturing of peptides
- Apr 2021Series A$36M
#11
Seed · San Diego, California · founded 2019 · 8 employees$3.1Mraised▾
Provider of research, development, and manufacturing services for biologic drugs
- Aug 2023Seed$2.8M
- Jun 2021Seed$285K
#12
Acquired · San Diego, California · founded 1998 · 281 employees$40.2Mraised▾
Operator of a biopharmaceutical company focused on developing and commercializing hospital specialty products that have a positive impact on society and provide value for the healthcare system. The company developed an antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD), thereby focusing on medicines that make a significant difference in the lives of patients and reduce the burden of disease.
- Aug 2009Grant (prize money)$2M
- Sep 2007Grant (prize money)$2M
- Nov 2005Series D$22.2M
- Jul 2005Grant (prize money)$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.